Abstract 6042
Background
Leadership is nursing is widely discussed and recognised as an important element in nursing services and indeed in health service development. Nurse leaders are in a prime position to facilitate and drive change within the healthcare setting. Nurse leaders can be role models within the workforce and integral in guiding and motivating teams to meet organisational goals. Whilst it often feels change within the clinical environment, occurs at a rapid rate or too frequently, resulting in a degree of change fatigue amongst nursing colleagues. Organisational change is often in response to advancements in medical knowledge, workforce demands or in this case, infrastructure change in response to increased demand upon a service. The authors work in a busy cancer centre, which delivers day case chemotherapy to approximately 130 patients a day. Delays resulting from patients attending day care in blocks of time resulted in bottle necks, meaning many faced long waits for their chemotherapy. A new scheduling system was implemented to focus booking patients based on chair availability and thus staggered more consistently across the day. The objective of the change was to improve patients’ attendance on our chemotherapy day unit, to prevent lengthy delays and streamline the process of delivering chemotherapy. The focus of this review, is how nursing leadership was instrumental in delivering change and how nurses are optimally positioned to drive change and manage projects in the healthcare setting.
Methods
A project was undertaken to implement a new electronic system for scheduling chemotherapy for a busy chemo day service. The project was led by oncology nurses within the service.
Results
The project outcome to implement a new electronic scheduling system was achieved in a timely manner. The project drivers did encounter some reticence, when colleagues faced new ways of working. Open and constant dialogue was maintained to ensure all stakeholders were fully apprised of the rationale for the change, the timescale and outcomes.
Conclusions
The importance of steady, intelligent leadership from nurses cannot be overestimated. Solidarity amongst nursing colleagues and allied health professionals is essential to optimise organisational efficacy and quality of care.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
5760 - Landscape of PD-L1 expression status in Chinese solid tumor patients.
Presenter: Yi Zhong
Session: Poster Display session 3
Resources:
Abstract
3733 - Anti-cancer and immunomodulatory effects of cobimetinib in triple negative breast cancer
Presenter: Chun-Yu Liu
Session: Poster Display session 3
Resources:
Abstract
4426 - Differential expression of immunoregulatory molecules and highly-associated cancer genes may provide novel insights into strategic trial design for therapeutics
Presenter: Jacob Adashek
Session: Poster Display session 3
Resources:
Abstract
2752 - Insights into the Tumor Immune Microenvironment using Tissue Phenomics to Drive Cancer Immunotherapy
Presenter: Martin Groher
Session: Poster Display session 3
Resources:
Abstract
5713 - Immune competent somatic mosaic model of colorectal cancer
Presenter: Stefania Napolitano
Session: Poster Display session 3
Resources:
Abstract
1898 - Genomic correlates of response to anti-PDL1 Atezolizumab in non-small-cell lung cancer OAK and POPLAR trials
Presenter: Hari Singhal
Session: Poster Display session 3
Resources:
Abstract
3246 - Erdafitinib (erda) versus available therapies in advanced urothelial cancer: A matching adjusted indirect comparison
Presenter: Yohann Loriot
Session: Poster Display session 3
Resources:
Abstract
3311 - High level of activity of Nivolumab anti-PD-1 immunotherapy and favorable outcome in metastatic/refractory MSI-H non-colorectal cancer: Results of the MSI cohort from the French AcSé program
Presenter: Christophe Tournigand
Session: Poster Display session 3
Resources:
Abstract
2314 - TP53 and ATM Co-mutation Predicts Response to Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
Presenter: Yu Chen
Session: Poster Display session 3
Resources:
Abstract
4692 - Immune cell biomarkers on neo-adjuvant chemo-immunotherapy treatment for resectable stage IIIA NSCLC patients
Presenter: Raquel Laza-Briviesca
Session: Poster Display session 3
Resources:
Abstract